These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 3033095)

  • 1. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.
    Matthews-Greer JM; Gilleland HE
    J Infect Dis; 1987 Jun; 155(6):1282-91. PubMed ID: 3033095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model.
    Gilleland HE; Gilleland LB; Matthews-Greer JM
    Infect Immun; 1988 May; 56(5):1017-22. PubMed ID: 2833440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice.
    Gilleland HE; Parker MG; Matthews JM; Berg RD
    Infect Immun; 1984 Apr; 44(1):49-54. PubMed ID: 6323316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preservation of pulmonary function by an outer membrane protein F vaccine. A study in rats with chronic pulmonary infection caused by Pseudomonas aeruginosa.
    Fox CW; Campbell GD; Anderson WM; Zavecz JH; Gilleland LB; Gilleland HE
    Chest; 1994 May; 105(5):1545-50. PubMed ID: 8181349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
    Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
    Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection.
    Gilleland HE; Gilleland LB; Staczek J; Harty RN; García-Sastre A; Palese P; Brennan FR; Hamilton WD; Bendahmane M; Beachy RN
    FEMS Immunol Med Microbiol; 2000 Apr; 27(4):291-7. PubMed ID: 10727884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection.
    Staczek J; Gilleland HE; Gilleland LB; Harty RN; García-Sastre A; Engelhardt OG; Palese P
    Infect Immun; 1998 Aug; 66(8):3990-4. PubMed ID: 9673294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
    Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
    Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht B; Knapp B; Hungerer K; Lücking C; Schmitt A; Domdey H
    J Biotechnol; 1996 Jan; 44(1-3):145-53. PubMed ID: 8717398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection.
    von Specht BU; Strigl G; Ehret W; Brendel W
    Infection; 1987; 15(5):408-12. PubMed ID: 3121520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
    Zaidi TS; Priebe GP; Pier GB
    Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
    Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
    APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus.
    Brennan FR; Jones TD; Gilleland LB; Bellaby T; Xu F; North PC; Thompson A; Staczek J; Lin T; Johnson JE; Hamilton WDO; Gilleland HE
    Microbiology (Reading); 1999 Jan; 145 ( Pt 1)():211-220. PubMed ID: 10206701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human anti-Pseudomonas aeruginosa outer membrane proteins IgG cross-protective against infection with heterologous immunotype strains of P. aeruginosa.
    Lee NG; Ahn BY; Jung SB; Kim YG; Lee Y; Kim HS; Park WJ
    FEMS Immunol Med Microbiol; 1999 Sep; 25(4):339-47. PubMed ID: 10497864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
    Cryz SJ; Sadoff JC; Fürer E; Germanier R
    J Infect Dis; 1986 Oct; 154(4):682-8. PubMed ID: 3091708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa.
    Staczek J; Bendahmane M; Gilleland LB; Beachy RN; Gilleland HE
    Vaccine; 2000 Apr; 18(21):2266-74. PubMed ID: 10717347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous
    Liu C; Pan X; Xia B; Chen F; Jin Y; Bai F; Priebe G; Cheng Z; Jin S; Wu W
    Front Immunol; 2018; 9():1737. PubMed ID: 30093906
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine.
    Ahmadi H; Tabaraie B; Maleknia S; Pormirzagholi F; Nejati M; Hedayati MH
    J Infect Dev Ctries; 2012 Oct; 6(10):721-6. PubMed ID: 23103894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa.
    Collins MS; Roby RE
    Am J Med; 1984 Mar; 76(3A):168-74. PubMed ID: 6424446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.